NDAORALTABLET
Approved
Dec 2020
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
4
Mechanism of Action
Adrenergic beta3-Agonists
Pharmacologic Class:
beta3-Adrenergic Agonist
Clinical Trials (4)
A Single-Dose Study of the Pharmacokinetics of Vibegron (MK-4618) in Adults With Hepatic Insufficiency (MK-4618-013)
Started Jan 2013
16 enrolled
Overactive Bladder
A Single Dose Study of the Pharmacokinetics of Vibegron (MK-4618) in Participants With Renal Insufficiency (MK-4618-014)
Started Jul 2012
32 enrolled
Overactive Bladder
A Study of the Pharmacokinetics and Pharmacodynamics of Vibegron (MK-4618) in Women With Overactive Bladder (MK-4618-004)
Started Feb 2012
4 enrolled
Overactive BladderOveractive Urinary Bladder
A Study of the Efficacy and Safety of Vibegron (MK-4618) in Participants With Overactive Bladder (OAB) (MK-4618-008)
Started Mar 2011
1,395 enrolled
Urinary Bladder, Overactive
Loss of Exclusivity
LOE Date
Jul 6, 2042
198 months away
Patent Expiry
Jul 6, 2042
Exclusivity Expiry
Dec 18, 2027